Click here to see the original post on AdPharm

Visit AdPharm.net for more pharmaceutical ads

For patients with life-threatening fungal infections
There's no time for a second chance

Voriconazole (VFEND, Pfizer) is a triazole antifungal medication that is generally used to treat serious, invasive fungal infections. These are generally seen in patients who are immunocompromised, and include invasive candidiasis, invasive aspergillosis, and certain emerging fungal infections.

More on Wikipedia

Brand name: Vfend
Generic name/category: Voriconazole, Antifungals, Triazoles
Company: Pfizer
Country/Market: USA, North America
Indication(s)/use: invasive fungal infections, candidiasis, aspergillosis, and certain emerging fungal infections.
Target: Healthcare Professionals (HCP)
Tagline: When it matters most
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – August 20, 2009

To see all of this brand's ads on AdPharm, click here
1 views
Sep 17, 2009

Visit AdPharm.net for more pharmaceutical ads

Administrez-vous le vaccin Gardasil aux jeunes femmes?
Recommand?© par le CCNI pour les filles et les femmes ag?©es de 9 a 26 ans.

Do you administer the Gardasil vaccine to young women?
Recommended by CCNI for girls and women ages 9 to 26 years.

Gardasil (Merck & Co.), also known as Gardisil or Silgard, is a vaccine against certain types of human papillomavirus (HPV).

Gardasil is designed to prevent infection with HPV types 16, 18, 6, and 11. HPV types 16 and 18 that currently cause about 70% of cervical cancer cases, and also cause some vulvar, vaginal, penile and anal cancers. HPV types 6 and 11 cause about 90% of genital warts cases.

Gardasil is only effective in preventing HPV infections, not in treating those already infected by HPV, and so the vaccine must be given before HPV infection occurs in order to be effective. For this reason it is recommended to administer the vaccine before adolescence and the onset of sexual activity.

More on Wikipedia

Brand name: Gardasil
Generic name/category: Vaccines, Papillomavirus
Company: Merck Frosst
Country/Market: Canada, North America
Indication(s)/use: human papillomavirus (HPV) types 6, 11, 16 and 18 infection prevention
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: single-page
Publication/Aired: Le M?©decin Du Qu?©bec – Septembre 2009

To see all of this brand's ads on AdPharm, click here
0 views
Sep 09, 2009

Visit AdPharm.net for more pharmaceutical ads

Thousands of stories

Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, the United States Department of Health and Human Services Panel on Antiretroviral Guidelines currently recommends the use of efavirenz in combination with lamivudine/zidovudine (Combivir) or tenofovir/emtricitabine (Truvada) as the preferred NNRTI-based regimens in adults and adolescents.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

The usual adult dose is 600 mg once a day. It is usually taken on an empty stomach at bedtime to reduce neurological and psychiatric adverse effects.

Efavirenz was combined with the popular HIV medication Truvada, which consists of tenofovir and emtricitabine, all of which are reverse transcriptase inhibitors. This combination of three medications approved by the U.S. Food and Drug Administration (FDA) in July 2006 under the brand name Atripla, provides HAART in a single tablet taken once a day. It results in a simplified drug regimen for many patients.

More on Wikipedia

Brand name: Sustiva
Generic name/category: Efavirenz, Non-nucleoside reverse transcriptase inhibitors, Alkynes, World Health Organization essential medicines
Company: Bristol-Myers Squibb BMS
Country/Market: USA, North America
Indication(s)/use: HIV combination therapy
Target: Healthcare Professionals (HCP)
Tagline: Thousands of stories
Medium: Web banner
Size/duration: 728X90
Publication/Aired: www.infectiousdiseasenews.com – September 2009
0 views
Sep 03, 2009

Visit AdPharm.net for more pharmaceutical ads